Groowe BETA / Newsroom

⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease

businesswire.com August 3, 2026 at 6:00 AM ET

RCKT The article announces positive clinical safety updates from initial patients treated with RP-A501 for Danon Disease, indicating promising results for the company's drug candidate.